Articles tagged "Hepatocellular carcinoma"

2022 American Transplant Congress
Exploring Individual Optimal Immunosuppression Management According to the Oncological Risk in Liver Transplanted Patients with Hepatocellular Carcinoma
K. Sasakik¹, S. Kimura², D. Soma³, K. Tomiyama⁴, M. Matthew⁴, M. Fruscione², C. Kubal³, D. Kwon⁵
¹Stanford University, Palo Alto, CA, ²Massachusetts General Hospital, Belmont, MA, ³Indiana University, Indianapolis, IN, ⁴University of Rochester, Rochester, NY, ⁵Cleveland Clinic, Cleveland, OH
*Purpose: Post-Liver transplant (LT) immunosuppression management is the only modifiable factor to prevent hepatocellular carcinoma (HCC) recurrence; however, the impact of immunosuppression on the HCC…
2021 American Transplant Congress
T Cell Repertoire Diversity in HCV-Associated Hepatocellular Carcinoma Patients Waitlisted for Liver Transplantation and Receiving Liver-Directed Therapy
K. Nunez, T. Sandow, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: T cell receptor (TCR) sequencing in hepatocellular carcinoma (HCC) patients revealed a diverse TCR repertoire in hepatitis B-associated HCC-infiltrating T cells. In this study,…
2021 American Transplant Congress
State-level Trend in the Prevalence of Non-alcoholic Steatohepatitis for Liver Transplant Candidates in the United States, 2001-2017
S. Chang¹, M. Wang¹, M. Pozo², D. Ladner², D. Borja-Cacho²
¹Washington University School of Medicine, Saint Louis, MO, ²Northwestern University, Chicago, IL
*Purpose: As variation in the prevalence of obesity across states continues to grow, the prevalence of nonalcoholic steatohepatitis (NASH) is also rising. However, little is…
2021 American Transplant Congress
Waitlist Outcomes for Patients with Hepatocellular Carcinoma Following the 2019 Exception Policy Change
K. Young¹, C. Enestvedt², W. Naugler¹, E. Maynard², A. Mitra¹, M. Wungiranirun¹, J. Jou¹, J. Ahn¹, M. Chang¹, D. Lhewa¹
¹Division of Gastroenterology and Hepatology, OHSU, Portland, OR, ²Division of Abdominal Organ Transplant, OHSU, Portland, OR
*Purpose: We aim to compare waitlist (WL) outcomes for HCC patients after the implementation of the most recent UNOS exception policy change on 5/1/2019.*Methods: All…
2021 American Transplant Congress
The Tumor-suppressor Signaling of the α1-na/k-atpase- Cav-1-src Complex at the Caveola in Nash Related Hepatocellular Carcinoma
U. S. Udoh¹, J. D. Sanabria¹, M. Banerjee¹, P. K. Rajan¹, M. Schade¹, J. A. Sanabria¹, A. Mallick¹, G. Smith¹, G. U. Udoh², K. Sodhi¹, S. Pierre², Z. Xie², J. Shapiro², J. Sanabria¹
¹Dept. of Surgery/ Marshall Institute for Interdisciplinary Research, Marshall University, Huntington,, WV, ²Marshall Institute for Interdisciplinary Research, Marshall University, Huntington,, WV
*Purpose: Hepatocellular Carcinoma (HCC) is the 2nd and fastest-growing cause of cancer related mortality worldwide, mainly from the metabolic cellular disturbances promoted by the epidemic…
2021 American Transplant Congress
Given the Potential Impact on Liver Transplant Selection, Revisiting the Current Standard of Diagnosis of Hepatocellular Carcinoma
K. Amarell, B. Fisher, B. Park, K. Ko, B. Kallakury
Department of Pathology & Laboratory Medicine, Georgetown University School of Medicine, Washington, DC
*Purpose: The current standard of diagnosis of hepatocellular carcinoma (HCC) relies on non-invasive radiographic methods, namely computerized tomography (CT) and/or magnetic resonance imaging (MRI). However,…
2021 American Transplant Congress
Effects of TIPS on Transplant Outcomes for HCC
C. L. Hanlon¹, D. Toy¹, Y. Liu¹, S. Zhou¹, K. Zhou², J. Kahn², L. Yuan²
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Internal Medicine - Department of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA
*Purpose: The purpose of this study is to examine effects of TIPS placement on response to locoregional therapy (LRT) and clinical outcomes after liver transplantation…
2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
S. Hsu, L. Jeng, H. Yang, A. Thorat
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
2021 American Transplant Congress
Review of 10-Year Liver Explant Pathology Impact on Outcomes in a Single Center
Y. K. Kwon¹, L. Sher¹, S. Khemichian², J. Kahn², Y. Genyk¹
¹Hepatobiliary and Abdominal Transplant Surgery, University of Southern California, Los Angeles, CA, ²Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA
*Purpose: Explant pathology (EP) is an important prognostic factor after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to correlate…
2021 American Transplant Congress
Intrahepatic Spatial Location of HCC Recurrence Following Loco-regional Therapy for Solitary Tumors Predicts a Higher Oncologic Risk & Increased Recurrence Post-transplant
A. Mathur, E. Baughan, S. Haider, A. Griesemer, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Loco-Regional therapy (LRT) for hepatocellular carcinoma (HCC) patients is an established bridge to Orthotopic Liver Transplantation (OLT). However, no large cohort data exist correlating…